Maine
Requires Coverage of Comprehensive Biomarker Testing
No
Highlighted Disparity
No racial disparities were found in Maine for these lung cancer metrics.
Lung Cancer Rates
New Cases:
- The rate of new lung cancer cases is 67.7 and significantly higher than the national rate of 53.6.
- Maine ranks 44th among all states, placing it in the below average tier.
- Over the last five years, the rate of new cases in Maine improved by 10%.
5-Year Survival Rate:
- The percent of people alive five years after being diagnosed with lung cancer (the survival rate) in Maine is 27.5%, which is not significantly different than the national rate of 28.4%.
- It ranks 25th among the 42 states with survival data, placing it in the average tier.
- Over the last five years, the survival rate in Maine improved by 26%.
Early Diagnosis:
- 28.2% of cases are caught at an early stage, which is not significantly different than the national rate of 27.4%.
- It ranks 18th among the 47 states with data on diagnosis at an early stage, placing it in the average tier.
- Over the last five years, the early diagnosis rate in Maine improved by 25%.
Lung Cancer Treatment
Biomarker Coverage:
- Maine has yet to require any insurance coverage of comprehensive biomarker testing, including for lung cancer, as of September 2024.
Surgical Treatment:
- Maine ranked 9th (out of the 47 states with available data) with 23.3% of cases undergoing surgery as part of the first course of treatment.
- This is significantly higher than the national rate of 20.7% and puts Maine in the above average tier.
- Over the last five years, the percent of cases undergoing surgery in Maine did not change significantly.
Lack of Treatment:
- Maine ranked 8th (out of the 47 states with available data) with 16.5% of cases not receiving any treatment.
- This is significantly lower than the national rate of 20.9% and puts Maine in the above average tier.
- Over the last five years, the percent of cases receiving no treatment in Maine did not change significantly.
Screening
Screening for High Risk:
- In Maine, 21.2% of those at high risk were screened, which was significantly higher than the national rate of 16.0%.
- It ranks 7th among all states, placing it in the above average tier.
Prevention
Tobacco Use:
- The smoking rate in Maine is 15.0% and significantly higher than the national rate of 12.9%.
- It ranks 33rd among all states, placing it in the below average tier.
Radon:
- In Maine, 36.5% of radon tests results were at or above the action level recommended by EPA.
- It ranks 37th among all states, placing it in the below average tier.
Racial & Ethnic Disparities
Black individuals:
- The rate of new lung cancer cases is 32.5 per 100,000 population among Black individuals in Maine, significantly lower than the rate of 55.1 among Black individuals nationally, and significantly lower than the rate of 68.0 among white individuals in Maine.
- Survival rates by race and ethnicity are not available for Maine at this time. Nationally, the five-year survival rate among Black individuals is 25.5%, 11% lower than among white Americans.
- Other lung cancer rates are not available for Black individuals in Maine due to too few cases over the time period to allow for accurate analysis.
Latino individuals:
- The rate of new lung cancer cases is 36.8 per 100,000 population among Latino individuals in Maine, not significantly different than the rate of 28.1 among Latino individuals nationally, and significantly lower than the rate of 68.0 among white individuals in Maine.
- State-level survival rates are not available for Latino individuals at this time. Nationally, the five-year survival rate among Latino individuals is 22.7%, not significantly different than the rate of 25.0% among white individuals.
- Other lung cancer rates are not available for Latino individuals in Maine due to too few cases over the time period to allow for accurate analysis.
Asian Americans or Pacific Islanders:
- The rate of new lung cancer cases is 28.5 per 100,000 population among Asian or Pacific Islanders individuals in Maine, not significantly different than the rate of 32.5 among Asian or Pacific Islanders individuals nationally, and significantly lower than the rate of 68.0 among white individuals in Maine.
- State-level survival rates are not available for Asian or Pacific Islander individuals at this time. Nationally, the five-year survival rate among Asian or Pacific Islander individuals is 28.6% and significantly higher than the rate of 25.0% among white individuals.
- Other lung cancer rates are not available for Asian or Pacific Islander individuals in Maine due to too few cases over the time period to allow for accurate analysis.
Indigenous Peoples:
- The rate of new lung cancer cases is 89.4 per 100,000 population among Indigenous Peoples (American Indians/Alaska Natives) in Maine, significantly higher than the rate of 39.9 among Indigenous Peoples nationally, and not significantly different than the rate of 68.0 among white individuals in Maine.
- State-level survival rates are not available for Indigenous Peoples at this time. Nationally, the five-year survival rate among Indigenous Peoples is 22.3% and not significantly different than the rate of 25.0% among white individuals.
- Other lung cancer rates are not available for Indigenous Peoples (American Indians/Alaska Natives) in Maine due to too few cases over the time period to allow for accurate analysis.
Summary
Despite the early diagnosis rate in Maine falling into the average tier, the state still has a lot of work to do to make sure that more of those at high risk for lung cancer are screened.
Maine has yet to require any insurance coverage of comprehensive biomarker testing, which can help determine what treatment options would be best for individuals with lung cancer and other diseases.
Maine falls into the above average tier for percent of patients receiving no treatment. Some patients do refuse treatment, but issues such as fatalism and stigma can prevent eligible patients from accessing treatment that may save or extend their lives. All patients should work with their doctors to establish a treatment plan and goals.
Page last updated: November 12, 2024